Purpose and Brief Explanation of Study:
Recently a medication called gabapentin has been successfully used to reduce stress in cats during veterinary visits. The dose of gabapentin used in younger cats to decrease stress may be inappropriate for cats with chronic kidney disease (CKD). Gabapentin is cleared from the body by the kidneys and an increase in the amount of time it takes the drug to leave the body has been demonstrated in humans with moderate kidney disease. In cats, some vets have experienced that higher gabapentin doses lead to sedation in feline CKD patients.
Objective of the trial:
- The purpose of this study is to demonstrate how a low dose of gabapentin is processed in the body of CKD cats in comparison to normal cats so that these patients can benefit from its use without over sedation.
What qualifies my cat for enrollment in this in this trial?
Cats with stable IRIS Stage 2, 3 or 4 chronic kidney disease (creatinine 2.0-8 mg/dL) are potentially eligible for entry into the study. Diagnostic tests performed before enrollment include a serum biochemistry profile, complete blood count, urinalysis, blood pressure and thyroid level (paid for by the study).
What does enrolling my cat in this clinical trial involve?
Once your cat is enrolled, the study involves bringing your cat into the clinic once for a drop off day visit. Your cat will drop off early in the morning, have a single oral dose of gabapentin administered, have a blood sample taken at 3 and 8 hours after administration, and then go home at the end of the day.
If your cat is eligible, you will receive a complimentary CBC, chemistry, urinalysis, blood pressure and thyroid level to confirm your cat’s health prior to participation. All costs of the visits and the medication are covered by the study.
In addition, you will receive $100 towards care at the Veterinary Medical Center. The study will not cover costs associated with management of CKD or the development of other illnesses unrelated to the study.
For more information regarding this study please contact:
Dr. Jessica Quimby